YDESNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as YDESW
YD Bio Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$6.12+0.20 (+3.38%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
YD Bio Ltd revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Sales of medical and other related products [Member] | $561.82K | $510.36K | – | 94.1% | +10.1% |
| Medical and related products [Member] | $280.77K | $292.86K | $146.85K | 47.0% | -4.1% |
| Drugs [Member] | $223.43K | $143.63K | $141.95K | 37.4% | +55.6% |
| Beauty products [Member] | $49.91K | – | – | 8.4% | – |
| Research and development of sales of contact lenses [Member] | $35.00K | – | – | 5.9% | – |
| Contact lenses [Member] | $35.00K | – | – | 5.9% | – |
| Nutritional products [Member] | $5.23K | $41.77K | $9.54K | 0.9% | -87.5% |
| Supplements [Member] | $2.47K | $32.10K | $51.79K | 0.4% | -92.3% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Taiwan | $561.82K | – | – | 94.1% | – |
| United States | $35.00K | – | – | 5.9% | – |
From the segment and revenue-disaggregation notes of YD Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.